K Milde-Langosch
Overview
Explore the profile of K Milde-Langosch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oliveira-Ferrer L, Hessling A, Trillsch F, Mahner S, Milde-Langosch K
Tumour Biol
. 2015 Jun;
36(11):9023-30.
PMID: 26084610
Ovarian cancer (OvCa) accounts for the highest tumor-related mortality among gynecological malignancies, but the underlying mechanisms are poorly understood. Glycosaminoglycans are abundantly present in ovarian tumors, and there is rising...
2.
Oliveira-Ferrer L, Kurschner M, Labitzky V, Wicklein D, Muller V, Luers G, et al.
J Cancer Res Clin Oncol
. 2015 Feb;
141(10):1715-26.
PMID: 25666264
Purpose: The transcription factor Fos-related antigen-1 (Fra-1) has been described to affect the morphology, motility and invasive potential of breast cancer cells. Since tumor cell adhesion plays an essential role...
3.
Oliveira-Ferrer L, Rossler K, Haustein V, Schroder C, Wicklein D, Maltseva D, et al.
Br J Cancer
. 2013 Dec;
110(3):753-63.
PMID: 24322891
Background: C-Fos was initially described as oncogene, but was associated with favourable prognosis in ovarian cancer (OvCa) patients. The molecular and functional aspects underlying this effect are still unknown. Methods:...
4.
Ihnen M, Wirtz R, Kalogeras K, Milde-Langosch K, Schmidt M, Witzel I, et al.
Br J Cancer
. 2010 Aug;
103(7):1048-56.
PMID: 20736952
Background: To analyse the discriminative impact of osteopontin (OPN) and activated leukocyte cell adhesion molecule (ALCAM), combined with human epidermal growth factor 2 (HER2) and oestrogen receptor (ER) in breast...
5.
Ihnen M, Kohler N, Kersten J, Milde-Langosch K, Beck K, Holler S, et al.
Dis Markers
. 2010 Apr;
28(2):71-8.
PMID: 20364042
Introduction: Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) gained increasing attention regarding tumorprogression and metastatic spread in breast cancer. The aim of this study was to examine ALCAM expression levels in...
6.
Mahner S, Baasch C, Schwarz J, Hein S, Wolber L, Janicke F, et al.
Br J Cancer
. 2008 Oct;
99(8):1269-75.
PMID: 18854825
Members of the Fos protein family dimerise with Jun proteins to form the AP-1 transcription factor complex. They have a central function in proliferation and differentiation of normal tissue as...
7.
Kilic E, Milde-Langosch K, Muller V, Wirtz R, Ihnen M
Pathologe
. 2008 Sep;
29 Suppl 2:347-52.
PMID: 18810438
Aims: Activated leukocyte cell adhesion molecule (ALCAM) is a cell surface immunoglobulin expressed in breast cancer (BC) and is assumed to be implicated in tumourigenesis and tumour progression. The importance...
8.
Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, et al.
Br J Cancer
. 2008 Sep;
99(6):930-8.
PMID: 18781150
The abilities of chemokines in orchestrating cellular migration are utilised by different (patho-)biological networks including malignancies. However, except for CXCR4/CXCL12, little is known about the relation between tumour-related chemokine expression...
9.
Ihnen M, Muller V, Wirtz R, Schroder C, Krenkel S, Witzel I, et al.
Breast Cancer Res Treat
. 2008 Jan;
112(3):419-27.
PMID: 18172759
Activated Leukocyte Cell Adhesion Molecule (ALCAM, also called CD 166, MEMD) as cell surface immunoglobulin is reported as prognostic marker in breast cancer, but its predictive value has not yet...
10.
Milde-Langosch K, Bamberger A, Rieck G, Grund D, Hemminger G, Muller V, et al.
Br J Cancer
. 2005 Jun;
92(12):2206-15.
PMID: 15928662
Extracellular-regulated kinases (ERK1, ERK2) play important roles in the malignant behaviour of breast cancer cells in vitro. In our present study, 148 clinical breast cancer samples (120 cases with follow-up...